Calcium Channel Dysfunction in Neurodegeneration
Introduction
Calcium Channel Dysfunction In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Calcium (Ca²⁺) signaling is fundamental to neuronal function, controlling neurotransmitter release, gene transcription, synaptic plasticity, and cellular survival. Dysregulation of calcium homeostasis is a hallmark of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). This pathway page explores the molecular mechanisms of calcium channel dysfunction and its contribution to neurodegeneration. [@surmeier2017]
Overview
[Neurons](/entities/neurons) maintain precise control over intracellular calcium concentrations through a sophisticated network of channels, pumps, buffers, and transporters. Disruption of this equilibrium leads to: [@khachaturian1994]
- [Excitotoxicity](/mechanisms/excitotoxicity)
- Mitochondrial dysfunction
- Oxidative stress
- Activation of apoptotic pathways
- Synaptic failure
...Calcium Channel Dysfunction in Neurodegeneration
Introduction
Calcium Channel Dysfunction In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Calcium (Ca²⁺) signaling is fundamental to neuronal function, controlling neurotransmitter release, gene transcription, synaptic plasticity, and cellular survival. Dysregulation of calcium homeostasis is a hallmark of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). This pathway page explores the molecular mechanisms of calcium channel dysfunction and its contribution to neurodegeneration. [@surmeier2017]
Overview
[Neurons](/entities/neurons) maintain precise control over intracellular calcium concentrations through a sophisticated network of channels, pumps, buffers, and transporters. Disruption of this equilibrium leads to: [@khachaturian1994]
- [Excitotoxicity](/mechanisms/excitotoxicity)
- Mitochondrial dysfunction
- Oxidative stress
- Activation of apoptotic pathways
- Synaptic failure
Mermaid diagram (expand to render)
Voltage-Gated Calcium Channel Types
High-Voltage Activated (HVA) Channels
| Channel Type | Gene | Primary Location | Function | [@stutzmann2007]
|--------------|------|------------------|----------| [@mattson2004]
| L-type (CaV1.x) | CACNA1A-D | Dendrites, cell body | Gene transcription, plasticity | [@popugaeva2018]
| N-type (CaV2.2) | CACNA1B | Presynaptic terminals | Neurotransmitter release | [@chan2009]
| P/Q-type (CaV2.1) | CACNA1A | Presynaptic terminals | neurotransmitter release | [@giacomello2005]
| R-type (CaV2.3) | CACNA1E | Dendrites, terminals | Residual Ca²⁺ influx | [@demuro2006]
Low-Voltage Activated (LVA) Channels
| Channel Type | Gene | Primary Location | Function | [@berridge2011]
|--------------|------|------------------|----------| [@palop2014]
| T-type (CaV3.x) | CACNA1G-I | Thalamic neurons | Pacemaking, burst firing | [@zndorf2011]
Calcium Dysregulation in Alzheimer's Disease
Store-Operated Calcium Entry (SOCE)
In AD, the endoplasmic reticulum (ER) calcium store becomes depleted due to: [@marongiu2009]
- Ryanodine Receptor (RyR) leak: Elevated RyR3 expression leads to ER Ca²⁺ leak
- IP₃ receptor dysfunction: Altered IP₃ signaling disrupts store release
- SERCA pump impairment: Reduced SERCA activity diminishes Ca²⁺ reuptake
The depleted ER triggers store-operated calcium entry (SOCE) through plasma membrane channels (ORAI1, STIM1), leading to excessive Ca²⁺ influx. [@ilari2020]
NMDA Receptor Dysfunction
- NR2B-containing NMDA receptors show increased activity in AD
- Extrasynaptic NMDA receptors promote Ca²⁺ overload
- Altered NMDA subunit composition (NR2A/NR2B ratio) affects signaling
L-Type Channel Alterations
- CaV1.2 channels show increased expression in AD neurons
- Enhanced L-type currents contribute to dendritic Ca²⁺ dysregulation
- Mode shifting observed in AD states
Calcium Dysregulation in Parkinson's Disease
Pacemaker Dysfunction
Dopaminergic neurons in the substantia nigra pars compacta (SNc) rely on L-type Ca²⁺ channels (CaV1.3) for autonomous pacemaking. This creates: [@wang2023]
- Constant Ca²⁺ influx during action potentials
- Enhanced mitochondrial oxidative stress
- Accelerated aging of dopaminergic neurons
Cav1.3 Channel Properties
- Activates at more negative voltages than CaV1.2
- Contributes substantially to the "slow pacemaker" current
- Risk factor for selective vulnerability of SNc neurons
Mitochondrial Calcium Overload
- Ca²⁺ accumulation in mitochondria
- Enhanced [ROS](/entities/reactive-oxygen-species) production
- Activation of mitochondrial permeability transition
- Triggering of apoptotic pathways
Therapeutic Targeting
Calcium Channel Blockers
| Drug/Compound | Target | Clinical Status | Notes |
|---------------|--------|-----------------|-------|
| Isradipine | CaV1.2 | Phase 2/3 (AD) | Failed to meet primary endpoints |
| Nilvadipine | CaV1.2 | Phase 3 (AD) | Mixed results |
| Flunarizine | CaV2.2 | Approved (migraine) | Potential neuroprotective effects |
| Ziconotide | CaV2.1 | Approved (pain) | Too toxic for chronic use |
Mode Gating Modulators
- CGP-37157: Mitochondrial Na⁺/Ca²⁺ exchange blocker
- RS-10046: RyR stabilizer in preclinical studies
SOCE Inhibitors
- DPB162-AE: STIM1 inhibitor (preclinical)
- ML-9: STIM1/Orai1 inhibitor (preclinical)
Molecular Components Table
| Component | Gene | Function | Disease Relevance |
|-----------|------|----------|-------------------|
| CaV1.2 | CACNA1C | L-type, dendritic Ca²⁺ | AD risk gene |
| CaV1.3 | CACNA1D | L-type, pacemaking | PD vulnerability |
| CaV2.2 | CACNA1B | N-type, presynaptic | Therapeutic target |
| CaV2.1 | CACNA1A | P/Q-type, release | Ataxia, migraine |
| CaV3.1 | CACNA1G | T-type, thalamic | Epilepsy, AD |
| STIM1 | STIM1 | SOCE sensor | ER Ca²⁺ store depletion |
| ORAI1 | ORAI1 | SOCE channel | Store-operated influx |
| RyR1-3 | RYR1-3 | ER Ca²⁺ release | AD increased leak |
| SERCA2 | ATP2A2 | ER Ca²⁺ reuptake | AD decreased activity |
| NCX | SLC8A1-3 | Mitochondrial Ca²⁺ | Mitochondrial dysfunction |
Disease-Specific Mechanisms
Alzheimer's Disease
Amyloid-β interaction: [Aβ](/proteins/amyloid-beta) directly interacts with L-type channels and RyRs
[Tau](/proteins/tau) hyperphosphorylation: Affects Ca²⁺ channel trafficking
Presenilin mutations: Alter ER Ca²⁺ homeostasis (FAD mutations)
Synaptic Ca²⁺ dysregulation: Impairs [LTP](/mechanisms/long-term-potentiation)mechanisms/long-term-potentiation) and memory formationParkinson's Disease
CaV1.3 vulnerability: Creates metabolic stress in SNc neurons
[α-Synuclein](/proteins/alpha-synuclein) effects: Modulates Ca²⁺ channel function
Mitochondrial Ca²⁺ overload: Triggers dopaminergic cell death
LRRK2 mutations: Affect Ca²⁺ signaling pathwaysAmyotrophic Lateral sclerosis
Motoneuron hyperexcitability: Enhanced Ca²⁺ influx
Presynaptic Ca²⁺ dysregulation: Affects glutamate release
Mitochondrial Ca²⁺ handling: Contributes to energy failure
[C9orf72](/entities/c9orf72) expansion: Alters Ca²⁺ homeostasisResearch Highlights
Key Publications
Bezprozvanny & Mattson (2008): Neuronal calcium signaling in AD - Trends Neurosci
Surmeier et al. (2017): Calcium and pacemaking in PD - Nat Rev Neurosci
Khachaturian (1994): Calcium hypothesis of aging and AD - Neurobiol Aging
Stutzmann (2007): RyR as therapeutic target in AD - Nat Rev Drug DiscovEmerging Concepts
- Neuroprotective strategies focusing on L-type blockers
- Mitochondrial calcium uniporter (MCU) targeting
- ER stress mitigation as therapeutic approach
- Gene therapy for Ca²⁺ channel modulation
Cross-Links
- [Calcium Dysregulation in AD](/mechanisms/calcium-dysregulation-ad)
- [Excitotoxicity Pathway](/mechanisms/excitotoxicity-pathway)
- [Neuronal Hyperexcitability](/mechanisms/neuronal-hyperexcitability)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-pathway)
- [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction-pathway)
External Links
- [PubMed - Research Papers](https://pubmed.ncbi.nlm.nih.gov/)
- [Allen Brain Atlas](https://brain-map.org/)
- [BrainSpan Atlas](https://brainspan.org/)
See Also
- [Cell Types Index](/cell-types)cell-types)
- [Brain Regions Index](/brain-regions)brain-regions)
Background
The study of Calcium Channel Dysfunction In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent Research Updates (2024-2026)
- Ultrasonic repression of TRPA1-dependent astrocyte reactivity confers neuroprotection in models of Lewy body dementia. (Transl Neurodegener, 2026). PMID: 41808144(https://pubmed.ncbi.nlm.nih.gov/41808144/)
- Class-Specific Antihypertensives and Alzheimer's Disease: Genotype- and Hypertension-Stratified Analysis. (Mol Neurobiol, 2026). PMID: 41806233(https://pubmed.ncbi.nlm.nih.gov/41806233/)
- Pro-tumoral Ca(2+) signaling is dependent on Slowpoke and Ca-α1T channels in Drosophila melanogaster glioma. (Sci Rep, 2026). PMID: 41792312(https://pubmed.ncbi.nlm.nih.gov/41792312/)
- Selective Ca(v)1.3 inhibition promotes survival of transplanted dopaminergic neurons via the CaMKII-p65-p53 pathway. (Stem Cell Reports, 2026). PMID: 41791389(https://pubmed.ncbi.nlm.nih.gov/41791389/)
- Calcium Signaling and Pathogenesis of Neurodegenerative Disorders: Potential Therapeutic Opportunities. (Cold Spring Harb Perspect Biol, 2026). PMID: 41786476(https://pubmed.ncbi.nlm.nih.gov/41786476/)
Confidence Assessment
🟡 Moderate Confidence
| Dimension | Score |
|-----------|-------|
| Supporting Studies | 15 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |
Overall Confidence: 43%
References
[Bezprozvanny I, Mattson MP, Neuronal calcium mishandling and the collapse of synaptic homeostasis in Alzheimer's disease (2008)](https://pubmed.ncbi.nlm.nih.gov/18305539/)
[Surmeier DJ, Schumacker PT, Guzman JD, et al, Calcium, mitochondria, and the pathophysiology of Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28676739/)
[Khachaturian ZS, Calcium hypothesis of Alzheimer's disease and brain aging (1994)](https://pubmed.ncbi.nlm.nih.gov/7838284/)
[Stutzmann GE, Calcium dysregulation, IP₃ signaling, and Alzheimer's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17901258/)
[Mattson MP, Calcium and neurodegeneration (2004)](https://pubmed.ncbi.nlm.nih.gov/15261481/)
[Popugaeva E, Pchitskaya E, Bezprozvanny I, Dysregulation of neuronal calcium homeostasis in Alzheimer's disease - a therapeutic opportunity? Cell Calcium (2018)](https://pubmed.ncbi.nlm.nih.gov/29631673/)
[Chan CS, Gertler TS, Surmeier DJ, Calcium homeostasis, selective vulnerability and Parkinson's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19285736/)
[Giacomello M, Barbiero L, Zotti G, et al, Ca²⁺ dysregulation in neurons from transgenic mice expressing mutant presenilin 1 (2005)](https://pubmed.ncbi.nlm.nih.gov/15718045/)
[Demuro A, Parker I, Cytotoxicity of intracellular Aβ42 aggregates involves Ca²⁺ release from endoplasmic reticulum stores (2006)](https://pubmed.ncbi.nlm.nih.gov/16337235/)
[Berridge MJ, Calcium signalling and Alzheimer's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21243582/)
[Palop JJ, Mucke L, Synaptic alterations in AD mouse models (2014)](https://pubmed.ncbi.nlm.nih.gov/25171369/)
[Zündorf G, Reiser G, Calcium dysregulation and its relationship to oxidative stress in neurodegenerative diseases (2011)](https://pubmed.ncbi.nlm.nih.gov/21361770/)
[Marongiu R, Spencer B, Crews L, et al, Mutant alpha-synuclein causes calcium dysregulation in Parkinson's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19791151/)
[Ilari A, Giunta CF, Di Nardo AA, et al, Targeting calcium signaling in ALS (2020)](https://pubmed.ncbi.nlm.nih.gov/32223576/)
[Wang Y, Shi Y, Wei H, Calcium dysregulation in Alzheimer's disease: from mechanisms to therapeutic strategies (2023)](https://pubmed.ncbi.nlm.nih.gov/36655123/)Pathway Diagram
The following diagram shows the key molecular relationships involving Calcium Channel Dysfunction in Neurodegeneration discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)